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ﻛﻮﺩﺍﻣﺎﻳﺎ)ﺑﻴﺘﺸﻴﺎ(ﺃﻭﻣﻴﺮﻱﻫﻮﻓﻄﺮﺍﻧﺘﻬﺎﺯﻱﻧﺎﺷﺊﻳﺘﺴﺒﺐﻓﻲﻋﺪﻭﻯﻗﺎﺗﻠﺔ.ﻧﻌﺮﺽ
ﻓﻲﻫﺬﺍﺍﻟﺘﻘﺮﻳﺮﺣﺎﻟﺔﻃﻔﻞﻳﺒﻠﻎﻣﻦﺍﻟﻌﻤﺮ٩ﺃﻋﻮﺍﻡﻳﻌﺎﻧﻲﻣﻦﺍﻟﻤﺘﻼﺯﻣﺔﺍﻟﻜﻠﻮﻳﺔ
ﺍﻟﻤﻘﺎﻭﻣﺔﻟﻠﻜﻮﺭﺗﻴﺰﻭﻥ.ﻛﺎﻥﺍﻟﻄﻔﻞﻋﻠﻰﺍﻟﻐﺴﻴﻞﺍﻟﺒﺮﻳﺘﻮﻧﻲﻭﺍﻟﺴﻴﻜﻠﻮﺳﺒﻮﺭﻳﻦ
ﻭُﻋﺮﺽﻋﻠﻴﻨﺎﺑﺤﺎﻟﺔﺍﻟﺘﻬﺎﺏﺍﻟﺼﻔﺎﻕﺑﺴﺒﺐﻛﻮﺩﺍﻣﺎﻳﺎﺃﻭﻣﻴﺮﻱ.ﺍﺳﺘﺠﺎﺏﺍﻟﻄﻔﻞ
ﻟﻠﻌﻼﺝﺑﻜﺎﺳﺒﻮﻓﻨﺠﻴﻦﺍﻟﺬﻱﻛﺎﻥﺍﻟﻔﻄﺮﻣﺘﺤﺴﺲﻟﻪﻭﺍﻟﺘﻲُﻭﺻﻔﺖﻟﻪﺑﻌﺪﺍﻹﺯﺍﻟﺔ
ﺍﻟﻔﻮﺭﻳﺔﻟﻠﻘﺜﻄﺎﺭﺍﻟﺒﺮﻳﺘﻮﻧﻲ.
ﺍﻟﻜﻠﻤﺎﺕﺍﻟﻤﻔﺘﺎﺣﻴﻪ:ﻛﻮﺩﺍﻣﺎﻳﺎﺃﻭﻣﻴﺮﻱ؛ﻛﺎﺳﺒﻮﻓﻨﺠﻴﻦ؛ﺍﻟﺘﻬﺎﺏﺍﻟﺼﻔﺎﻕ
Abstract
Kodamaea (Pichia) ohmeri is an emerging fatal opportu-
nistic fungal infection. We describe the case of a 9-year-
old boy known to have steroid-resistant nephrotic syn-
drome. The child, on peritoneal dialysis and cyclosporine,
presented with peritonitis related to K. ohmeri. The pa-
tient’s condition was cured by immediate removal of the
peritoneal catheter and treatment with Caspofungin,
which was prescribed for susceptible fungal infection.
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Kodamaea (Pichia) ohmeri is a yeast belonging to the fungi
kingdom and the Saccharomycetes class, Kodamaea genus,
and K. ohmeri species, which was previously called Yama-
dazma ohmeri.1
It is the teleomorphic form of Candida guilliermondii var.
membranaefaciens and is widely used in the food industry for
the fermentation of fruits, pickles, and rinds.1
The genus Kodamaea currently comprises five species:
K. anthrophila, K. kakaduensis, K. laetipori, K. nitidulidarum,
and K. ohmeri.2 Twenty-seven cases have been reported in
the medical literature with different presentations and risk
factors (Table 1).6,9,10,12e19 Most of the patients were
immune-compromised and diabetic, but a few cases were
immune-competent. Among them, only one patient was
treated with caspofungin,4 and another patient was
successfully treated with micafungin.3 There were 10
reported deaths despite antifungal therapy with
amphotericin and fluconazol (Table 1).6,8,9,12,15,17,20,23
In this report, we describe the case of a 9-year-old child
with ESRD on peritoneal dialysis complicated by Kodamaea
(pichia) ohmeri peritonitis that was successfully treated with
caspofungin.
The case
A nine-year-old boy was referred to our hospital with a
diagnosis of steroid-resistant nephrotic syndrome. He washis is an open access article under the CC BY-NC-ND license
16/j.jtumed.2015.08.003
Table 1: A summary of the clinical characteristics of the cases of K. ohmeri infection in the most recent medical literature.3
Case Reference
Year
Country Age
Sex
Risk factors Source Antifungal Outcome
1 8 (2007) Korea 11/12
M
Burkitt’s lymphoma
Neutropenia, CVC
Blood FCZ Died
2 8 (2007) Korea 41/M Alcohol, KA, TB, CVC Blood No antifungal Survived
3 8 (2007) Korea 47/M DM, CRF, CVC Blood FCZ, AMB Died
4 8 (2007) Korea 4/F TOF, CVC Blood FCZ, AMB Died
5 8 (2007) Korea Neonate F Premature, CVC Blood No antifungal Survived
6 20 (2007) Spain 82/F DM, CRF Blood AMB Died
7 21 (2008) e 38/F AML, Hemochromatosis Blood FCZ, AMB Survived
8 23 (2008) India Neonate M Prematurity Blood FCZ, AMB Died
9 22 (2009) Brazil 3/F Ascaris, Peritonitis, CVC,
Multiple ABX
Blood Liposomal
AMB
Survived
10 11 (2009) Taiwan 71/M DM, TinaPedis, Cellulitis Blood FCZ, AMB Survived
11 4 (2009) Taiwan 55/M Alcoholic, Hepatitis,
Duodenal ulcer, CVC
Blood FCZ, Caspofungin Survived
12 24 (2009) India 38/F HIV, CD4-7%, Absolute CD4
111 cell/mm3
Oral
Swab
FCZ e
13 3 (2010) USA 34/M Asthma, Alcohol,
Thrombophlebitis
Blood Micafungin Survived
14 Present case (2014) Saudi Arabia
(SA)
9/M CRF, Peritoneal dialysis,
Cyclosporine
Peritoneal fluid FCZ, AMB,
Caspofungin
Survived
PM: pacemaker, DM: diabetes mellitus, CVC: central venous catheter, SCC: Squamous cell carcinoma, VP: ventriculoperitoneal shunt,
KA: ketoacidosis, CRF: chronic renal failure, ALL: acute lymphoblastic leukaemia, CML: chronic lymphoblastic leukaemia, HCV:
hepatitis C virus, PAC: porta catheter, AMB: amphotericin B, FCZ: fluconazol, ABX: antibiotics, TOF: tetralogy of fallot, TB: tuber-
culosis, and NEC: necrotizing enterocolitis. Table adapted and modified with permission received from the publisher. Mycopathologia
(2010) 170:223e228.
Figure 1: Growth of K. ohmeri in sabouraud dextrose agar,
KFSH&RC.
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phritis based on a renal biopsy prior to his presentation to us.
He was receiving 50 mg of cyclosporine every 12 h, 12.5 mg
of captopril every 8 h, and 100 mg of labetalol every 12 h and
was discharged for follow up in the outpatient clinic.
Seven months ago, the patient was admitted to a local
hospital complaining of cough, vomiting, decreased oral
intake, abdominal pain, and generalized oedema with a fever
up to 39 C for a duration of 1 month. Peritoneal dialysis was
started every other day, but his abdominal pain was severe
and did not improve. A peritoneal fluid culture was obtained,
and a Candida infection was identified; the patient was
started on 100 mg of intravenous fluconazole once daily and
was transferred to our institute for peritoneal catheter
removal.
On admission to our centre, his temperature was 36.6 C,
and he had a pulse rate of 118 bpm, an RR of 36/min, a Bp of
128/96 mmHg, a Wt of 19.4 Kg, an Ht 120 cm, and a BMI of
13.5 kg/m2. During hospitalization, his fever spiked to
39.4 C; he was started on pipracillinetazobactam (tazocin)
and vancomycin in addition to fluconazole, and the perito-
neal catheter was removed. Investigations found a WBC
count of 17, a PLT count of 465, and a negative blood cul-
ture. The chest X-ray showed bilateral small pleural effusion.
Peritoneal fluid was collected for culture and sensitivity (c/s).
The fluconazole was changed to ambisome, and the perito-
neal dialysis was switched to haemodialysis (HD) through a
femoral line inserted in the left side. The organism was
identified as yeast, and the ambisome was changed to cas-
pofungin. An abdominal ultrasound was performed and
found no evidence of collection, although the kidneys were
small and echogenic with multiple cortical cysts related to
end-stage renal disease, without hepatic or splenic lesions,and diffuse mild small bowel thickening, suggestive of en-
teritis. The final identification of the yeast isolated from the
peritoneal fluid was K. ohmeri (previously known as Pichia
ohmeri).
Our microbiology lab detectedK. ohmeri using the Vitek 2
biosysteme and sub culturing on sabouraud dextrose agar,
which showed white rough colonies of yeast (Figure 1) that
failed to grow in mycological agar. Additionally, the
sample turned blue-grey in response to CHROMagar
Candida chromogenic agar growth medium. The API 20C
assay was used for confirmation.
Table 2: The Kodamaea (Pichia) ohmeri suscep-
tibility test (KFSH&RC).
Amphotericin B 0.5 mg/l
Anidulafungin 0.12
Micafungin 0.12
Caspofungin 0.5
Voriconazol 0.03
Itraconazol 0.06
Fluconazol 4
Posaconazol 0.03
5 Flurocytosine 0.06
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tion showed that the organism was susceptible to caspo-
fungin and amphotericin B, and according to the CLSI
definition of the break point,5 it was susceptible to all other
antifungal therapy.
The patient’s general condition improved, and the patient
became a febrile. We continued treatment with caspofungin
for three weeks and achieved complete recovery.
Discussion
Kodamaea ohmeri yeast has been described in the litera-
ture and mostly causes blood stream infections
(Table 1).6,9,12,14e19 Nearly all of the reported cases are
associated with risk factors such as diabetes mellitus,
neutropenia, malignancy, catheter-related infections such
as those of the central venous catheter or the ventriculo-
peritoneal-shunt, and peritoneal dialysis (Table 1).6,9,10,12e
19 Our patient presented with peritonitis secondary to
peritoneal dialysis. Additionally, the patient was an
immune-compromised child on cyclosporine. As the child
was treated in a local hospital, their laboratory results did
not identify the yeast or provide treatment such as flucona-
zol. After the removal of the peritoneal catheter, the anti-
fungal was changed from fluconazol to ambisome, and then
caspofungin was started based on the identification of the
fungus as a yeast. The general condition of the child
improved in regard to his abdominal pain and the disap-
pearance of the fever.
The patient completed three weeks of caspofungin, ach-
ieved a complete recovery from his peritonitis and was dis-
charged home.
The K. ohmeri yeast was first discovered in an immuno-
compromised patient in 1998.6 It is an emerging
opportunistic pathogen and should not be considered to be
a contamination.7 There is limited data on the risk factors,
laboratory analyses, treatment and prevention of K. ohmeri
infection.7 A literature review (Table 1)6,9,10,12e19 indicated
that K. ohmeri can be resistant to fluconazole, is associated
with poor outcomes and treatment with amphotericin B is
optimal. However, our case was successfully managed with
caspofungin, which was selected because the patient was
still symptomatic (including fever and abdominal pain)
despite ambisome therapy for a week. Until now, no
standard therapeutic regimen had been identified.
In 2009, a 55-year-old Taiwanese man presented with
alcoholic hepatitis and peptic ulcer disease with CVC for
parental nutrition, and he developed fungemia, which wassuccessfully treated with the removal of the CVC and cas-
pofungin for a total of 2 weeks.4
The identification of K. ohmeri yeast in the laboratory is
possible with the commercially available Vitek and API 20C
assays, but the API 20C is considered the gold standard for
the identification of K. ohmeri and other yeast species.8
CHROMagar Candida chromogenic agar growth medium
is a useful tool for the detection of yeast species.8 This tool
is based on the growth of coloured colonies in which the
colour changed from pink to blue.8e10
In children, three cases have been reported in prema-
ture neonates, and six additional cases have been reported
among patients aged 8 months to 14 years old, indicating
that there is no age specification for this infection but that
the underlying risk factors play a major role in acquiring
the infection (Table 1).8,9,18 The source of the infection in
our case was most likely the dialysis fluid. Seventy percent
of the reported cases were catheter related, indicating that
a breakdown of the skin mucosal barrier is a significant
risk factor.11 The duration of the treatment is varied in
the previous reports, as there is no recognized number
of cases yet available. The duration may be longer in
cases of endocarditis with prophylactic antifungal
therapy.14Conclusion
Kodamaea ohmeri is an emerging fatal opportunistic
fungal infection that should be specifically included in the
differential diagnoses of immune-compromised patients
and those with indwelling catheters. A high index of sus-
picion and early diagnosis and treatment are necessary for
optimal recovery.Author contribution
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